Supplement Table 1. Surgical Morbidity

perative Morbidity	No. of patients
orbidity	63
Intraabdominal	18
Superficial	17
Paralytic	14
Mechanical	8
nonia	6
S	4
ng	4
	orbidity Intraabdominal Superficial Paralytic Mechanical nonia

Supplement Table 2. Logistic regression analysis for adjuvant therapy

		Odds Ratio	95% CI	p value
Age (years)	per 10 years	0.71	0.58 - 0.88	0.002
	5-10cm <i>v</i> s <5cm	1.48	0.78 - 2.84	0.255
Tumor size (cm)	>10cm <i>v</i> s <5cm	3.87	1.72 - 8.74	0.001
	6-10 <i>v</i> s <5	1.54	0.82 - 2.88	0.456
Mitosis (/50HPF)	>10 <i>v</i> s <5	3.54	1.84 - 6.79	0.000
Tumor rupture	Presence <i>vs</i> Absence	3.69	1.43 - 9.52	0.007
PS	1-or-more vs 0	0.55	0.31 - 0.99	0.046

Case	Dx	Origin	Tumor size (cm)	Mitosis	KIT	DOG1	CD34	Desmin	KIT • PDGFRA mutation	Comments
1	Local Central	peritoneum	7.8	9 20	positive +/-	negative	positive +/-		None	Sarcoma, NOS: KIT(-), DOG1(-)
2	Local Central	small intestine	9.0	5 68	positive negative	negative	+/- negative	negative	n.e.	Sarcoma, NOS: KIT(-), DOG1(-)
3	Local Central	small intestine	15.0	20 104	negative	negative	negative		None	Sarcoma, NOS: KIT(-), DOG1(-)
4	Local Central	stomach	34.0	10 19	positive negative	negative	+/-		None	Leiomyosarcoma suspected: Desmin (+), SMA (+/-)
5	Local Central	stomach	6.5	10 1	positive negative	negative	positive positive	negative	None	Leiomyosarcoma suspected: Desmin (-), SMA (+/-)
б	Local Central	small intestine	12.8	0 0	positive negative	negative	negative negative		None	Desmoid: nuclear β -catenin (+)
7	Local Central	larynx	4.0	50 1	positive negative	+/-	positive negative	positive	None	compatible with Leiomyosarcoma: SMA(+), Desmin (+)
8	Local Central	esophagus	7.2	5 0	positive negative	negative	positive negative	positive	None	Leiomyoma: KIT (-), DOG1 (-)
9	Local Central	colon	15.0	0 0	+/- negative	negative	negative negative		None	Desmoid: β-catenin exon 3 Thr41Ala
10	Local Central	peritoneum	8.0	5 72	positive negative	negative	negative negative	negative	None	Sarcoma, NOS: KIT(-), DOG1(-)
11	Local Central	small intestine	8.0	1 0	+/- negative	negative	positive negative		None	Desmoid: nuclear β-catenin+, β-catenin exon 3 Thr41Ala
12	Local Central	stomach	2.8	18 0	positive negative	negative	positive +/-	positive	None	Leiomyosarcoma suspected: Desmin (+), SMA(+)
13	Local Central	colon	13.5	42 84	positive +/-	+/-	negative negative		None	Sarcoma, NOS: KIT(-), DOG1(-)
14	Local Central	omentum	10.0	7 1	positive negative	negative	positive positive		None	Solitary fibrous tumor NAB2-STAT61 fusion gene (+),
15	Local Central	mesenterium	5.5	200 14	positive negative	negative	positive +/-	positive	None	Leiomyosarcoma suspected: Desmin (+) in local hospital
16	Local Central	stomach	9.5	23 1	+/- negative	negative	positive negative	negative	None	Sarcoma, NOS: KIT(-), DOG1(-)
17	Local Central	stomach	6.0	10 118	negative negative	negative	positive negative	negative	None	Sarcoma, NOS: KIT(-), DOG1(-)
18	Local Central	small intestine	14.0	2 0	positive negative	negative	negative negative	negative	None	Desmoid: β-catenin exon 3 Thr41Ala
19	Local Central	mesenterium	4.5	81 33	positive negative	negative	negative negative		None	Leiomyosarcoma: α-SMA (+), Desmin (+)

Supplement Table 3. Cases of complete discordance between local and central pathology

Common features of non-GISTs in the central pathology are:KIT-negative & DOG1-negative and no mutations in KIT and PDGFRA, although they were diagnosed KIT-positive or –weaklypositive, and/or CD34-positive.

Total		GIST (N=515)	Non-GIST (N=19)	P value	
Age (median, IQR; years)		65 (56-72)	60 (40-72)	0.076	
Gender	Male	280 (54.4%)	14 (73.7%)	0.154	
	Female	235 (45.6%)	5 (26.3%)	0.154	
	Esophagus	6 (1.2%)	1 (5.3%)		
	Stomach	313 (60.8%)	5 (26.3%)		
Location	Small intestine	158 (30.7%)	5 (26.3%)	<0.0001	
	Colon & rectum	30 (5.8%)	2 (10.5%)		
	Others	8 (1.6%)	6 (31.6%)		
Neoadjuvant	(-)	456 (88.5%)	19 (100%)	0.233	
Neoadjuvant	(+)	59 (11.5%)	0 (0%)	0.200	
Surgony	Open	373 (72.4%)	14 (73.7%)	1.000	
Surgery	Laparoscopic	142 (27.6%)	5 (26.3%)		
Curability of surgery	R0	498 (96.7%)	19 (100%)	0.889	
	R1	17 (3.3%)	0 (0%)		
Tumor size (median, IQR: cm)		7.5 (5.5 – 11.3)	8.0 (6.0 – 13.5)	0.343	
	unavailable	1	0	0.040	
Mitosis (median, IQR: /50HPF) at local		10 (5 – 23)	10 (5 – 23)	0.666	
	unavallable	38	0	0.000	
	No	442 (85.8%)	17 (89.5%)	1.000	
Tumor rupture	Yes	64 (12.4%)	2 (10.5%)		
	Unknown	9 (1.7%)	0 (0%)		
	Spindle	433 (84.1%)	13 (68.4%)		
Histological types	Epithelioid	15 (2.9%)	2 (10.5%)	0.113	
listological types	Mixed	45 (8.7%)	1 (5.3%)		
	unavailable	22 (4.3%)	3 (15.8%)		
	(+)	499 (96.9)	0 (0)	<0.0001	
KIT in central pathology	(±)	12 (2.3)	2 (10.5)		
Rin in central pathology	(-)	3 (0.6)	17 (89.5)	\0.0001	
	unavailable	1 (0.2)	0 (0)		
	(+)	501 (97.3)	0 (0)	<0.0001	
DOG1 in central pathology	(±)	11 (2.1)	2 (10.5)		
	(-)	2 (0.4)	17 (89.5)	\U.UUU	
	unavailable	1 (0.2)	0 (0)		
	KIT	456 (88.5%)	0 (0%)	<0.0001	
Genotyping	PDGFRA	18 (3.5%)	0 (0%)		
Genotyping	Wild type	19 (3.7%)	18 (94.7%)	<0.0001	
	unavailable	22 (4.3%)	1 (5.3%)		

Supplement Table 4. Comparison of clinicopathological features between GIST and non-GIST

Supplement Table 5. The members of the STAR ReGISTry Study Group

Following Institutions and Hospitals, and Investigators in the parentheses are the members of the STAR ReGISTry Study Group; Osaka Police Hospital (Takuro Saito), Hokkaido University Hospital (Yoshito Komatsu), Kobe City Medical Center General Hospital (Masato Kondo), Kanagawa Cancer Center (Tsutomu Hayashi), Kyoto University Hospital (Yoshiharu Sakai), National Cancer Center Hospital East (Naoto Gotoda), Chiba Cancer Center Hospital (Nobuhiro Takiguchi), Hyogo Prefectural Amagasaki General Medical Center (Atsuhiko Maki), Kumamoto University Hospital (Hideo Baba), Juntendo University Shizuoka Hospital (Hajime Orita), Niigata Cancer Center Hospital (Hiroshi Yabusaki), Yokohama Rosai Hospital (Gaku Chiguchi, Kyoto Katsura Hospital (Dai Manaka), Tokai University Hospital (Kazuhito Nabeshima), Asahikawa-Kosei General Hospital (Hiromitsu Akabane), Obihiro-Kosei General Hospital (Koichi Ono), Keio University Hospital (Norihito Wada), Toyama Prefectural Central Hospital (Masahide Kaji), Gifu University Hospital (Kazuhiro Yoshida, Matsuyama Red Cross Hospital (Ikuo Takahashi), Osaka General Medical Center (Kazumasa Fujitani), Nara Medical University Hospital (Sohei Matsumoto), Osaka City General Hospital (Yutaka Tamamori), Tottori University Hospital (Hiroaki Saito), Kitano Hospital The Tazuke Kofukai Medical Research Institute (Shugo Ueda), Kawasaki Medical School Hospital (Masahiro Yamamura, Japanese Red Cross Kumamoto Hospital (Eiji Tanaka), Jichi Medical University Hospital (Hirofumi Fujii), Yamaguchi University Hospital (Shigefumi Yoshino), St. Luke's International Hospital (Akihiro Suzuki), University Hospital Kyoto Prefectural University of Medicine (Eigo Otsuji), Tokyo Medical University Hachioji Medical Center (Shigeyuki Kawachi), Osaka University Hospital (Tsuyoshi Takahashi, Osaka City University Hospital (Kazuya Muguruma, Niigata University Medical and Dental Hospital (Suguru Ishikawa), Sanda City Hospital (Masaaki Mitsutsuji), Saiseikai Kumamoto Hospital (Hiroshi Takamori), Kimitsu Chuo Hospital (Takashi Kaiho), Hitachi General Hospital (Akihiro Sako), Aichi Cancer Center Hospital (Seiji Ito), National Hospital Organization Chiba Medical Center (Masahiro Mori), Center Hospital of the National Center for Global Health and Medicine (Makoto Tokuhara), University of Yamanashi Hospital (Yoshihiko Kawaguchi), Hiroshima City Asa Citizens Hospital (Naoki Hirabayashi), Ehime University Hospital (Motohira Yoshida), Yokohama

Municipal Citizen's Hospital (Masazumi Takahashi), Hyogo Prefectural Kakogawa Medical Center (Shiro Takase), Kitasato University East Hospital (Keishi Yamashita), Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (Yoshiaki Iwasaki), Kizawa Memorial Hospital (Yutaka Ozeki), Keiyukai Sapporo Hospital (Yasunori Nishida), Sakai City Medical Center Yutaka Kimura), Iwate Medical University (Keisuke Koeda), Kaizuka City Hospital (Toshimasa Tsujinaka), Japanese Red Cross Nagoya Daini Hospital (Hiroshi Kanie), National Hospital Organization Shikoku Cancer Center (Shinji Hato), Seichokai Fuchu Hospital (Junya Morimoto), Sendai City Medical Center (Hiroshi Honda), National Hospital Organization Kure Medical Center and Chugoku Cancer Center (Hirotaka Tashiro), Kobe University Hospital (Yoshihiro Kakeji), National Hospital Organization Kyoto Medical Center (Hiroaki Hata), Toyama University Hospital (Toshiro Sugiyama), Sapporo Medical University Hospital (Takayuki Nobuoka), Teikyo University Hospital (Ryoji Fukushima), South Miyagi Medical Center (Katsuro Sugiyama), Osaka Rosai Hospital (Junichi Hasegawa), Tenri Hospital (Tsunehiro Yoshimura), National Cancer Center Hospital (Atsuo Takashima), Yokohama City University Medical Center (Chikara Kunisaki), Saiseikai Utsunomiya Hospital (Hiroharu Shinozaki), Steel Memorial Muroran Hospital (Naoto Senmaru), Toyonaka Municipal Hospital (Hiroshi Imamura), Oita University Hospital (Satoshi Otsu), Nagoya University Hospital (Daisuke Kobayashi), Matsushita Memorial Hospital (Akinori Noguchi), Hakodate Goryoukaku Hospital (Akinori Takagane), Tokyo Women's Medical University Yachiyo Medical Center (Atsushi Mitsunaga), Kansai Rosai Hospital (Shigeyuki Tamura), Yao Municipal Hospital (Jin Matsuyama), Nishinomiya Municipal Central Hospital (Yoshio Oka, lizuka Hospital (Kiyoshi Kajiyama), Tokyo Women's Medical University Hospital (Takuji Yamada), Tokyo Medical University Hospital (Sumito Hoshino), Hiroshima University Hospital (Hideki Ohdan), National Hospital Organization Okayama Medical Center (Tomokazu Kakishita), The Jikei University School of Medicine Hospital (Katsuhiko Yanaga), Yokohama City University Hospital (Yasushi Rino), Japanese Red Cross Ashikaga Hospital (Takayuki Takahashi), Chiba University Hospital (Hisahiro Matsubara), Okayama Rosai Hospital (Masahiro Ishizaki), Kansai Medical University (Songtae Kim), Ishikawa Prefectural Central Hospital (Noriyuki Inaki), Shimane University Hospital (Noriyuki Hirahara), National Hospital Organization Kyushu Cancer Center (Masaru Morita), Sanjo General

Hospital (Tatsuo Kanda), Kawasaki Medical School Hospital (Tomoki Yamatsuji, Hoshigaoka Medical Center (Mitsutoshi Tatsumi), Suita Municipal Hospital (Chikara Ebisui), International University of Health and Welfare, Mita Hospital (Yoshifumi Ikeda), Iwate Prefectural Central Hospital (Tsukasa Inoue), Yamagata University Hospital (Wataru Kimura), Otemae Hospital (Hiroyuki Nakaba), Saiseikai Nara Hospital (Takamune Shibaji), National Hospital Organization Osaka Minami Medical Center (Taichi Tatsubayashi), Nagano Municipal Hospital (Masahiro Sakon), National Hospital Organization Tokyo Medical Center (Yo Isobe), Tokushima University Hospital (Mitsuo Shimada), Hyogo College of Medicine College Hospital (Mitsuru Sasako), Naha City Hospital (Hirofumi Tomori), Rinku General Medical Center (Koichi Demura), Kawasaki Hospital (Masahiro Fujikawa), National Hospital Organization Saitama National Hospital (Hirohito Ishizuka), Kashiwara Municipal Hospital (Masanari Tendo), Saitama Medical University International Medical Center (Shinichi Sakuramoto), Shimane Prefectural Central Hospital (Akiyoshi Kanazawa), Yamagata Prefectural Central Hospital (Norimasa Fukushima), Saga-ken Medical Center Koseikan (Seiji Sato), Okayama Saiseikai General Hospital (Takaomi Takahata), Clinical Research Institute National Hospital Organization Kyushu Medical Center (Tetsuya Kusumoto), Osaka International Cancer Institute (Takeshi Omori), Tohoku University Hospital (Masanobu Takahashi), Akita University Hospital (Masahiro Inoue), Kagawa Prefectural Central Hospital (Norimitsu Tanaka), Hiroshima City Hiroshima Citizens Hospital (Motoki Ninomiya), Hikone Municipal Hospital (Yasufumi Teramura)